 Ryan Kammeyer
Concepts (134)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Encephalitis | 2 | 2025 | 142 | 1.310 |
Why?
| | Cognitive Dysfunction | 3 | 2025 | 468 | 1.250 |
Why?
| | Multiple Sclerosis | 4 | 2025 | 489 | 0.980 |
Why?
| | Lupus Vasculitis, Central Nervous System | 1 | 2024 | 14 | 0.840 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2024 | 122 | 0.810 |
Why?
| | Neurofilament Proteins | 1 | 2024 | 79 | 0.810 |
Why?
| | Fatigue | 1 | 2025 | 366 | 0.760 |
Why?
| | Cerebral Veins | 1 | 2021 | 16 | 0.670 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2023 | 238 | 0.660 |
Why?
| | Central Nervous System Diseases | 1 | 2021 | 74 | 0.630 |
Why?
| | Cerebral Hemorrhage | 1 | 2021 | 125 | 0.620 |
Why?
| | Microvessels | 1 | 2021 | 97 | 0.610 |
Why?
| | Hashimoto Disease | 1 | 2019 | 10 | 0.600 |
Why?
| | Sarcoidosis | 1 | 2021 | 163 | 0.570 |
Why?
| | Venous Thrombosis | 1 | 2021 | 196 | 0.560 |
Why?
| | Down Syndrome | 4 | 2024 | 525 | 0.490 |
Why?
| | Hemoglobin SC Disease | 1 | 2016 | 14 | 0.480 |
Why?
| | Embolism, Fat | 1 | 2016 | 11 | 0.470 |
Why?
| | Purpura, Thrombotic Thrombocytopenic | 1 | 2016 | 14 | 0.470 |
Why?
| | Consciousness Disorders | 1 | 2016 | 25 | 0.470 |
Why?
| | Nystagmus, Pathologic | 1 | 2016 | 19 | 0.470 |
Why?
| | Cerebral Infarction | 1 | 2016 | 47 | 0.470 |
Why?
| | Multiple Organ Failure | 1 | 2016 | 120 | 0.450 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2016 | 156 | 0.430 |
Why?
| | Diagnostic Errors | 1 | 2016 | 178 | 0.420 |
Why?
| | Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 2 | 2024 | 22 | 0.400 |
Why?
| | Quality of Life | 1 | 2025 | 3211 | 0.380 |
Why?
| | Autoantibodies | 2 | 2023 | 1509 | 0.380 |
Why?
| | Biomarkers | 1 | 2024 | 4302 | 0.380 |
Why?
| | Ventricular Fibrillation | 1 | 2013 | 64 | 0.370 |
Why?
| | Neuromyelitis Optica | 2 | 2026 | 140 | 0.370 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2013 | 339 | 0.290 |
Why?
| | Epilepsy | 2 | 2023 | 390 | 0.270 |
Why?
| | Seizures | 3 | 2025 | 485 | 0.230 |
Why?
| | Child | 9 | 2025 | 22740 | 0.230 |
Why?
| | Complement Inactivating Agents | 1 | 2026 | 74 | 0.220 |
Why?
| | Atrophy | 1 | 2025 | 199 | 0.210 |
Why?
| | Adolescent | 8 | 2024 | 22577 | 0.210 |
Why?
| | Janus Kinase Inhibitors | 1 | 2024 | 28 | 0.210 |
Why?
| | Humans | 21 | 2026 | 145785 | 0.200 |
Why?
| | Paraneoplastic Syndromes, Nervous System | 1 | 2023 | 14 | 0.200 |
Why?
| | Laryngismus | 1 | 2023 | 10 | 0.200 |
Why?
| | Neuroglia | 1 | 2024 | 174 | 0.190 |
Why?
| | Dystonia | 1 | 2023 | 27 | 0.190 |
Why?
| | Genetic Testing | 2 | 2023 | 483 | 0.190 |
Why?
| | Piperidines | 1 | 2024 | 222 | 0.190 |
Why?
| | Male | 11 | 2026 | 73012 | 0.180 |
Why?
| | Case-Control Studies | 3 | 2024 | 3634 | 0.180 |
Why?
| | Self Report | 1 | 2025 | 876 | 0.160 |
Why?
| | Electroencephalography | 1 | 2024 | 563 | 0.160 |
Why?
| | Pyrimidines | 1 | 2024 | 530 | 0.160 |
Why?
| | Interferon-gamma | 1 | 2023 | 784 | 0.150 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2026 | 992 | 0.150 |
Why?
| | Neuropsychological Tests | 1 | 2024 | 1137 | 0.150 |
Why?
| | Female | 9 | 2026 | 79045 | 0.140 |
Why?
| | Middle Aged | 5 | 2026 | 36309 | 0.140 |
Why?
| | Magnetic Resonance Imaging | 3 | 2025 | 3916 | 0.130 |
Why?
| | Platelet Count | 1 | 2016 | 94 | 0.120 |
Why?
| | Tachycardia | 1 | 2016 | 58 | 0.120 |
Why?
| | Adult | 5 | 2026 | 40882 | 0.120 |
Why?
| | Depression | 1 | 2025 | 1559 | 0.110 |
Why?
| | Brain | 2 | 2025 | 2969 | 0.110 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2016 | 95 | 0.110 |
Why?
| | Fatal Outcome | 1 | 2016 | 305 | 0.110 |
Why?
| | Retrospective Studies | 8 | 2026 | 17330 | 0.110 |
Why?
| | Young Adult | 4 | 2024 | 14254 | 0.110 |
Why?
| | Neurons | 1 | 2024 | 1652 | 0.110 |
Why?
| | T-Lymphocytes | 1 | 2023 | 1998 | 0.110 |
Why?
| | Receptor, IGF Type 1 | 1 | 2015 | 64 | 0.110 |
Why?
| | Emergencies | 1 | 2016 | 174 | 0.110 |
Why?
| | Overnutrition | 1 | 2015 | 28 | 0.110 |
Why?
| | Aged | 3 | 2026 | 26217 | 0.110 |
Why?
| | Genetic Predisposition to Disease | 1 | 2023 | 2399 | 0.100 |
Why?
| | Dyspnea | 1 | 2016 | 250 | 0.100 |
Why?
| | Immunotherapy | 3 | 2024 | 668 | 0.100 |
Why?
| | Glucose Intolerance | 1 | 2015 | 142 | 0.100 |
Why?
| | Hemoglobins | 1 | 2016 | 386 | 0.100 |
Why?
| | Swine | 2 | 2013 | 826 | 0.100 |
Why?
| | Cardiac Output | 1 | 2013 | 179 | 0.090 |
Why?
| | Pulmonary Ventilation | 1 | 2013 | 82 | 0.090 |
Why?
| | Coronary Circulation | 1 | 2013 | 134 | 0.090 |
Why?
| | Carotid Arteries | 1 | 2013 | 208 | 0.090 |
Why?
| | Regional Blood Flow | 1 | 2013 | 514 | 0.080 |
Why?
| | Spectroscopy, Fourier Transform Infrared | 1 | 2010 | 85 | 0.080 |
Why?
| | Insulin-Secreting Cells | 1 | 2015 | 392 | 0.080 |
Why?
| | Insulin Resistance | 1 | 2015 | 1244 | 0.060 |
Why?
| | Blood Pressure | 1 | 2013 | 1782 | 0.060 |
Why?
| | Aquaporin 4 | 1 | 2026 | 101 | 0.060 |
Why?
| | Muscle, Skeletal | 1 | 2015 | 1791 | 0.050 |
Why?
| | Aging | 1 | 2015 | 1973 | 0.050 |
Why?
| | Child, Preschool | 3 | 2024 | 11868 | 0.050 |
Why?
| | Diplopia | 1 | 2023 | 28 | 0.050 |
Why?
| | Occipital Lobe | 1 | 2023 | 26 | 0.050 |
Why?
| | Antibodies, Antinuclear | 1 | 2023 | 62 | 0.050 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 1 | 2023 | 55 | 0.050 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2023 | 133 | 0.050 |
Why?
| | Disease Models, Animal | 1 | 2013 | 4568 | 0.040 |
Why?
| | Neuroimaging | 1 | 2024 | 300 | 0.040 |
Why?
| | Recurrence | 1 | 2023 | 1139 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2023 | 674 | 0.040 |
Why?
| | Activities of Daily Living | 1 | 2022 | 444 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2023 | 892 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2024 | 869 | 0.030 |
Why?
| | B-Lymphocytes | 1 | 2023 | 872 | 0.030 |
Why?
| | Animals | 3 | 2015 | 38106 | 0.030 |
Why?
| | Mental Disorders | 1 | 2024 | 1171 | 0.030 |
Why?
| | Cell Count | 1 | 2015 | 319 | 0.030 |
Why?
| | Animals, Genetically Modified | 1 | 2015 | 247 | 0.030 |
Why?
| | Luminescent Proteins | 1 | 2015 | 186 | 0.030 |
Why?
| | Biological Transport | 1 | 2015 | 424 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2015 | 407 | 0.020 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2015 | 317 | 0.020 |
Why?
| | Recombinant Fusion Proteins | 1 | 2015 | 666 | 0.020 |
Why?
| | Zebrafish Proteins | 1 | 2015 | 314 | 0.020 |
Why?
| | Bruch Membrane | 1 | 2010 | 6 | 0.020 |
Why?
| | Hyperglycemia | 1 | 2015 | 381 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 5925 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2022 | 6465 | 0.020 |
Why?
| | Prospective Studies | 1 | 2023 | 8078 | 0.020 |
Why?
| | Laminin | 1 | 2010 | 72 | 0.020 |
Why?
| | Biomimetics | 1 | 2010 | 41 | 0.020 |
Why?
| | Molecular Conformation | 1 | 2010 | 141 | 0.020 |
Why?
| | Hydrogen Bonding | 1 | 2010 | 169 | 0.020 |
Why?
| | Adsorption | 1 | 2010 | 153 | 0.020 |
Why?
| | Zebrafish | 1 | 2015 | 532 | 0.020 |
Why?
| | Hydrophobic and Hydrophilic Interactions | 1 | 2010 | 192 | 0.020 |
Why?
| | Surface Properties | 1 | 2010 | 386 | 0.020 |
Why?
| | Glucose | 1 | 2015 | 1050 | 0.020 |
Why?
| | Infant | 1 | 2022 | 10091 | 0.020 |
Why?
| | Collagen | 1 | 2010 | 457 | 0.020 |
Why?
| | Disease Progression | 1 | 2015 | 2865 | 0.020 |
Why?
| | Amino Acids | 1 | 2010 | 519 | 0.020 |
Why?
| | Peptides | 1 | 2010 | 1000 | 0.010 |
Why?
| | Insulin | 1 | 2015 | 2516 | 0.010 |
Why?
|
|
Kammeyer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|